Jubilant Pharmova Ltd.

“Jubilant Pharmova's North American nuclear pharmacy network is a genuine moat asset with a multi-year theranostics tailwind, but it is trapped inside a conglomerate whose blended economics — dragged by structurally declining US generics, a subscale CRMS segment, and legacy acquisition debt — prevent consolidated ROIC from clearing cost of capital. Management has demonstrated one strong capital allocation decision in the radiopharma rollup but has repeatedly failed to exit the generics drag, eroding execution credibility. At 26x forward earnings with meaningful balance sheet leverage and a non-trivial FDA tail risk to the sole pillar of the thesis, the current price offers no margin of safety. The 10-year base-case return of 2–3x is uninspiring relative to the risks assumed, and conviction is insufficient to deploy new capital when better-allocated compounder alternatives exist.”